ArticleFrontiers in pharmacology2026
Liu Wei formula ameliorates EGFR-induced malignant glioma progression by regulating EGFR/PI3K/AKT pathway and T-cell antitumor immunity.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Gliomas, common malignant intracranial tumors, are associated with a poor prognosis and pose a significant threat to human health. Liu Wei formula (LWF), a century-old herbal formula developed by Tai Kang Gu Lou Hospital of Nanjing University of Chinese Medicine, shows clinical efficacy against glioma. However, the fundamental molecular mechanisms and pathways through which LWF exerts its therapeutic effects remain largely unclear. Materials and Methods: A LUC-GL261 mouse model was established to assess the Results: LWF significantly suppressed tumor growth in mice. Network pharmacology and experimental validation revealed inhibition of the EGFR/PI3K/AKT pathway and downregulation of related genes. Flow cytometry analysis revealed a significant increase in the proportion of CD8 Conclusion: The above results indicate that LWF, through its main antitumor components baicalin and luteolin, suppresses malignant progression of EGFR-induced glioma by blocking the EGFR/PI3K/AKT pathway and enhancing T-cell expansion and function. This study offers a dual contribution: it presents clinical candidates for EGFR-driven glioma therapy and introduces a novel framework for determining the functional basis of LWFs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.